𝔖 Bobbio Scriptorium
✦   LIBER   ✦

PGI23 Cost Effectiveness of Retreatment of Patients with Chronic Hepatitis C (Chc) Who Do Not Respond to Peginterferon Alpha and Ribavirin for 48 Weeks Vs. Peginterferon Alfa and Ribavirin for 72 Weeks

✍ Scribed by M. Fonseca; G. Tannus; E. Parisi

Book ID
119311679
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
57 KB
Volume
15
Category
Article
ISSN
1098-3015

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Randomized trial of peginterferon alfa-2
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response
✍ Maria Buti; Yoav Lurie; Natalia G. Zakharova; Natalia P. Blokhina; Andrzej Horba πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 197 KB πŸ‘ 2 views

The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RBV) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatm

187 Efficacy and safety of 22 weeks of m
187 Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2A (40KD) (PEGASYSβ„’) alone versus peginterferon alfa-2A (40KD) plus ribavirin(COPEGUSβ„’) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2A (40KD) plus ribavirin: an open, multicenter, randomized trial
✍ Jean-Pierre Bronowicki; Denis Ouzan; Arnaud Tzanck; Tarik Asselah; Herve Desmora πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 233 KB